132 related articles for article (PubMed ID: 30264826)
1. Tolerability of Current Antiretroviral Single-Tablet Regimens.
Domingo P; Mateo MG; Gutierrez MDM; Vidal F
AIDS Rev; 2018; 20(3):141-149. PubMed ID: 30264826
[TBL] [Abstract][Full Text] [Related]
2. Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials.
Lathouwers E; Wong EY; Brown K; Baugh B; Ghys A; Jezorwski J; Mohsine EG; Van Landuyt E; Opsomer M; De Meyer S;
AIDS Res Hum Retroviruses; 2020 Jan; 36(1):48-57. PubMed ID: 31516033
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide in the treatment of HIV-1.
Negredo E; Clotet B
Expert Opin Pharmacother; 2018 Jun; 19(8):929-934. PubMed ID: 29767543
[TBL] [Abstract][Full Text] [Related]
4. Population Pharmacokinetic Analysis of Darunavir and Tenofovir Alafenamide in HIV-1-Infected Patients on the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen (AMBER and EMERALD Studies).
Ackaert O; McDougall D; Pérez-Ruixo C; Pérez-Ruixo JJ; Jezorwski J; Crauwels HM
AAPS J; 2021 Jun; 23(4):82. PubMed ID: 34100149
[TBL] [Abstract][Full Text] [Related]
5. Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve patients with HIV-1: subgroup analyses of the phase 3 AMBER study.
Rashbaum B; Spinner CD; McDonald C; Mussini C; Jezorwski J; Luo D; Van Landuyt E; Brown K; Wong EY
HIV Res Clin Pract; 2019 Feb; 20(1):24-33. PubMed ID: 31303147
[No Abstract] [Full Text] [Related]
6. Darunavir-cobicistat-emtricitabine-tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era.
Squillace N; Bozzi G; Colella E; Gori A; Bandera A
Drug Des Devel Ther; 2018; 12():3635-3643. PubMed ID: 30464395
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial.
Orkin C; Molina JM; Negredo E; Arribas JR; Gathe J; Eron JJ; Van Landuyt E; Lathouwers E; Hufkens V; Petrovic R; Vanveggel S; Opsomer M;
Lancet HIV; 2018 Jan; 5(1):e23-e34. PubMed ID: 28993180
[TBL] [Abstract][Full Text] [Related]
8. A four-drug combination oral tablet of darunavir, cobicistat, emtricitabine, and tenofovir alafenamide for the treatment of HIV-1 infection in adults.
Muccini C; Castagna A
Expert Rev Anti Infect Ther; 2023; 21(11):1167-1176. PubMed ID: 37800640
[TBL] [Abstract][Full Text] [Related]
9. Bioequivalence of the Once-Daily Single-Tablet Regimen of Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Compared to Combined Intake of the Separate Agents and the Effect of Food on Bioavailability.
Crauwels HM; Baugh B; Van Landuyt E; Vanveggel S; Hijzen A; Opsomer M
Clin Pharmacol Drug Dev; 2019 May; 8(4):480-491. PubMed ID: 30412360
[TBL] [Abstract][Full Text] [Related]
10. Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study.
Huhn GD; Eron JJ; Girard PM; Orkin C; Molina JM; DeJesus E; Petrovic R; Luo D; Van Landuyt E; Lathouwers E; Nettles RE; Brown K; Wong EY
AIDS Res Ther; 2019 Aug; 16(1):23. PubMed ID: 31464642
[TBL] [Abstract][Full Text] [Related]
11. Week 96 resistance analyses of the once-daily, single-tablet regimen (STR) darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in adults living with HIV-1 from the phase 3 randomized AMBER and EMERALD trials.
Lathouwers E; Weinsteiger S; Baugh B; Ghys A; Jezorwski J; Mohsine EG; Van Landuyt E; De Meyer S
J Med Virol; 2021 Jun; 93(6):3985-3990. PubMed ID: 33300183
[TBL] [Abstract][Full Text] [Related]
12. Symtuza
Gómez Ayerbe C; Santos González J; Palacios Muñoz R
Enferm Infecc Microbiol Clin (Engl Ed); 2018 Dec; 36 Suppl 2():17-21. PubMed ID: 30545467
[TBL] [Abstract][Full Text] [Related]
13. Body mass index increase and weight gain among people living with HIV-1 initiated on single-tablet darunavir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide in the United States.
Emond B; Rossi C; Côté-Sergent A; Bookhart B; Anderson D; Lefebvre P; Lafeuille MH; Donga P
Curr Med Res Opin; 2022 Feb; 38(2):287-298. PubMed ID: 34812097
[TBL] [Abstract][Full Text] [Related]
14. Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.
Deeks ED
Drugs; 2018 Jul; 78(10):1013-1024. PubMed ID: 29915897
[TBL] [Abstract][Full Text] [Related]
15. Fixed dose darunavir boosted with cobicistat combined with emtricitabine and tenofovir alafenamide fumarate.
Cevik M; Orkin C
Curr Opin HIV AIDS; 2018 Jul; 13(4):315-319. PubMed ID: 29528852
[TBL] [Abstract][Full Text] [Related]
16. Assessment of swallowability and acceptability of scored darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed-dose combination (FDC) tablets in HIV-1-infected children aged ≥6 to <12 years, using matching placebo tablets: A randomized study.
Van Hemelryck S; Van Landuyt E; Hufkens V; Vanveggel S
Antivir Ther; 2024 Apr; 29(2):13596535241248282. PubMed ID: 38725258
[TBL] [Abstract][Full Text] [Related]
17. Symtuza
Galindo Puerto MJ
Enferm Infecc Microbiol Clin (Engl Ed); 2018 Dec; 36 Suppl 2():22-30. PubMed ID: 30545468
[TBL] [Abstract][Full Text] [Related]
18. Impact of Splitting or Crushing on the Relative Bioavailability of the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen.
Brown K; Thomas D; McKenney K; Reeder M; Simonson RB; Bicer C; Nettles RE; Crauwels H
Clin Pharmacol Drug Dev; 2019 May; 8(4):541-548. PubMed ID: 30508308
[TBL] [Abstract][Full Text] [Related]
19. Week 96 subgroup analyses of the phase 3, randomized AMBER and EMERALD trials evaluating the efficacy and safety of the once daily darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen in antiretroviral treatment (ART)-naïve and -experienced, virologically-suppressed adults living with HIV-1.
Huhn GD; Wilkin A; Mussini C; Spinner CD; Jezorwski J; El Ghazi M; Van Landuyt E; Lathouwers E; Brown K; Baugh B;
HIV Res Clin Pract; 2020 Dec; 21(6):151-167. PubMed ID: 33528318
[TBL] [Abstract][Full Text] [Related]
20. Pharmacology of Symtuza
Curran A; Navarro J
Enferm Infecc Microbiol Clin (Engl Ed); 2018 Dec; 36 Suppl 2():10-16. PubMed ID: 30545466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
